Search company, investor...
Sinovac Biotech company logo

Sinovac Biotech

Founded Year



Corporate Minority - P2P | IPO

About Sinovac Biotech

Sinovac Biotech (NASDAQ: SVA) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies.

Headquarters Location

No. 39 Shangdi Xi Road

Beijing, Beijing, 100085,


+86 10 8289 0088

Missing: Sinovac Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sinovac Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Sinovac Biotech News

Chinese artificial heart maker Yongrenxin Medical Instrument raises $100m

Mar 13, 2023

10 March, 2023 Yongrenxin Medical Instrument, known as the maker of the implantable artificial heart Evaheart, has raised $100 million in a Series A round led by vaccines maker Sinovac Biotech. The round, joined by the private equity investment arm of China Taiping Insurance Holdings, the longest-running insurance brand in the country, as well as existing shareholder Vivo Capital, will help the firm to build a healthcare platform for heart failure and severe heart diseases, the firm said in a release on Thursday. Founded in June 2014, the Chongqing-based firm’s first artificial heart won government approval in September 2019, per local state media. Several local medical development firms in the country have also been greenlighted by the government including Rocor Medical Technology and  Suzhou Tongxin Medical Equipment. Previously, Yongrenxin snapped “several tens of millions” in US dollars from Vivo Capital in 2021. Yongrenxin’s fundraising announcement comes at a time when there has been a significant funding drop in the industry — the medical device and equipment industry booked $610.6 million in Q4 2022, down by 33.3% from $916 million in the same period of 2021, according to DealStreetAsia’s proprietary data.

Mar 4, 2023
Pandemic blues

Sinovac Biotech Frequently Asked Questions (FAQ)

  • When was Sinovac Biotech founded?

    Sinovac Biotech was founded in 2009.

  • Where is Sinovac Biotech's headquarters?

    Sinovac Biotech's headquarters is located at No. 39 Shangdi Xi Road, Beijing.

  • What is Sinovac Biotech's latest funding round?

    Sinovac Biotech's latest funding round is Corporate Minority - P2P.

  • Who are the investors of Sinovac Biotech?

    Investors of Sinovac Biotech include Sino Biopharmaceutical.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.